| Issue Date |
Title |
Author(s) |
| 2011 |
A 3-DAY ORAL APREPITANT REGIMEN PROVIDES SUPERIOR PREVENTION OF CINV OVER STANDARD THERAPY IN CHINESE PATIENTS RECEIVING HIGH-DOSE CISPLATIN |
Zhang, Li;Cheng, Ying;Zhang, Hong-Yu;Zhou, Caicun;Han, Baohui;Zhang, Yiping;Huang, Cheng;Chang, Jianhua;Song, Xiang Q.;Liang, Jun;Liang, Houjie;Bai, Chunxue;Yu, Shiying;Chen, Jia;Wang, Jie;Pan, Hongming;Carides, Alexandra;Chitkara, Denesh |
| 2013 |
The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries |
Sun, Guo-ping;Sun, Yan;Xu, Rui-hua;Xu, Jian-Ming;Li, Jin;Wang, Jin-Wan;Qin, Shukui;Feng, Ji Feng;Ba, Yi;Shen, Lin;Bai, Yu-Xian;Sun, Yihong;Pan, Hongming;Cheng, Ying;Yu, Shiying;Zhong, Haijun;Bai, Li;Luo, Rongcheng;Kobayashi, Mikiro;Ohtsu, Atsushi |
| Feb-2021 |
Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study |
Jiang, Zefei;Hu, Xichun;Zhang, Qingyuan;Sun, Tao;Yin, Yongmei;Li, Huiping;Yan, Min;Tong, Zhongsheng;Oppermann, Christina Pimentel;Liu, Yunpeng;Costa, Romulo;Li, Man;Chen, Xi;Cheng, Ying;Ouyang, Quchang;Liao, Ning;Wang, Xiaojia;Wu, Xinhong;Feng, Jifeng;Hegg, Roberto;Setty, Govindbabu Kanaka;Agarwal, Amit;Bajpai, Jyoti;Cheng, Jing;Girotto, Gustavo;Goswami, Chanchal;Hu, Wenjing;Huang, Jian;Portugal, M. A. Coccia;Yang, Jin;Zheng, Rongsheng;Franke, Fabio Andre;Liu, Qiang;Liu, Yunjiang;Lu, Yongkui;Souza, Cristiano;Yu, Shiying;Kilara, Nalini;Panchal, Harsha;Singh, Ashish;Nag, Shona;Liu, Jian;Rapoport, Bernardo;Tabane, Neonyana Keorapetse Rebecca;Wang, Hongxia;Wang, Ning;Han, Rubing;Zhang, Wanli |
| 2019 |
Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study |
Ma, Fei;Ouyang, Quchang;Li, Wei;Jiang, Zefei;Tong, Zhongsheng;Liu, Yunjiang;Li, Huiping;Yu, Shiying;Feng, Jifeng;Wang, Shusen;Hu, Xichun;Zou, Jianjun;Zhu, Xiaoyu;Xu, Binghe |
| 2018 |
A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab |
Xu, Binghe;Ma, Fei;Ouyang, Quchang;Li, Wei;Jiang, Zefei;Tong, Zhongsheng;Liu, Yunjiang;Li, Huiping;Yu, Shiying;Feng, Jifeng;Wang, Shusen;Hu, Xichun;Zhu, Xiaoyu;Zou, Jianjun |
| 2018 |
A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab |
Xu, Binghe;Ma, Fei;Ouyang, Quchang;Li, Wei;Jiang, Zefei;Tong, Zhongsheng;Liu, Yunjiang;Li, Huiping;Yu, Shiying;Feng, Jifeng;Wang, Shusen;Hu, Xichun;Zhu, Xiaoyu;Zou, Jianjun |
| 1-Jun-2022 |
RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. |
Sheng, Xinan;He, Zhisong;Shi, Yanxia;Luo, Hong;Han, Weiqing;Yao, Xin;Shi, Benkang;Liu, Jiyan;Hu, Changlu;Liu, Ziling;Guo, Hongqian;Yu, Guohua;Ji, Zhigang;Yu, Shiying;Hu, Yi;Guo, Jianming;Ying, Jianming;Fang, Jianmin;Zhou, Aiping;Guo, Jun |
